The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from GlobeNewswire (a Nasdaq OMX company)

Merrimack Pharmaceuticals Announces Timing of Second Quarter 2012 Investor Conference Call

Wednesday, August 01, 2012

Merrimack Pharmaceuticals Announces Timing of Second Quarter 2012 Investor Conference Call06:00 EDT Wednesday, August 01, 2012CAMBRIDGE, Mass., Aug. 1, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Second Quarter 2012 Investor Conference Call and webcast at 11 a.m., Eastern time, on Friday, August 10. The call will cover an update on Merrimack's progress as well as a summary of second quarter financials. A press release detailing the information to be discussed on the call will be issued before market open on Friday, August 10. Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 16536247. A dial-in replay of the call will be available approximately two hours after the close of the call until August 17, 2012 by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international) and using the conference identification number: 16536247.  A listen-only webcast of the call can be accessed in the Investor Relations section of Merrimack's website, http://investors.merrimackpharma.com and a replay of the call will be archived there.  About Merrimack Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.Forward-looking statements Any statements in this press release about Merrimack's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.CONTACT: Investor & Media Contact: Kathleen Petrozzelli Gallagher Corporate Communications, Merrimack 617-441-1043, kgallagher@merrimackpharma.com Media Contact: Betsy Stevenson RaymondStevenson Healthcare Communications 860-984-1424, betsy@raymondstevenson.com